Qiagen NV (LTS:0RLT) Receipts from Customers

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RLT Qiagen NV LTS:0RLT
69 GF Score
Price €38.58
GF Value €43.45
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Qiagen NV Receipts from Customers?

Receipts from Customers only applicable to companies reporting Cash Flow from Operations in direct method.

LTS:0RLT
69GF Score
Qiagen NV LTS:0RLT
Receipts from Customers is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Qiagen NV (LTS:0RLT) Overvalued in 2026?

Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued. The current stock price of €38.58 is trading 11.2% below its estimated GF Value™ of €43.45. GuruFocus considers Qiagen NV to be Modestly Undervalued.

Key valuation signals for LTS:0RLT:

  • Receipts from Customers:
  • GF Value™: €43.45 vs. price of €38.58 (11.2% below fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RLT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Qiagen NV Business Description

Address Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Qiagen NV is a Netherlands-based provider of sample-to-insight solutions for molecular biology, serving life sciences research and molecular diagnostics customers. Its portfolio includes sample collection and stabilization products, nucleic acid extraction and purification kits, assays, instrumentation, and bioinformatics software used to analyze DNA, RNA, and proteins. The company operates through segments including Sample Technologies, Diagnostic Solutions, PCR/Nucleic Acid Amplification, and Genomics/Next-Generation Sequencing. Qiagen sells primarily consumables, which generate the large majority of revenue, supplemented by instrument sales and related services. Customers include academic and pharmaceutical research laboratories, clinical diagnostic laboratories, hospitals, and applied testing markets such as forensics and food safety. Geographically, the Americas represent the largest share of sales, followed by Europe, the Middle East and Africa, and Asia-Pacific. Qiagen also develops companion diagnostics with pharmaceutical partners and offers automation platforms that integrate its consumables and instruments into laboratory workflows.
69GF Score

Get the complete analysis for LTS:0RLT

Receipts from Customers is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€38.58
Price
€43.45
GF Value